https://www.selleckchem.com/pr....oducts/act001-dmamcl
The same applies for patients with podocytopathy-related focal segmental glomerulosclerosis lesions. From now on, IgAN and podocytopathy trials without SGLT2 inhibition as background therapy and without glomerular filtration rate decline as primary outcome criterion will be of limited value. These and other potential implications will trigger broad discussions and secondary research activities with conclusions difficult to predict today. However, one is for sure Nephrology after the DAPA-CKD trial will be not the same as it was be
Aimer
Commentaire
Partagez
